Department of Chemistry, Atomic & Mass Spectrometry - A&MS Research Unit, Ghent University, Campus Sterre, Krijgslaan 281 - S12, 9000, Ghent, Belgium.
Department of Intractable Diseases, Research Institute, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku, Tokyo, 162-8655, Japan.
Sci Rep. 2020 Oct 2;10(1):16389. doi: 10.1038/s41598-020-71764-7.
We have examined potential changes in the isotopic compositions of Fe, Cu and Zn (using multi-collector inductively coupled plasma-mass spectrometry) and the corresponding concentrations (using inductively coupled plasma-atomic emission spectrometry) in plasma from hematological malignancy (HM) patients and assessed their prognostic capability. Together with clinical laboratory test values, data were examined in view of a 5-years survival prediction. Plasma Cu and Zn isotope ratios and their concentrations were significantly different in HM patients compared to matched controls (P < 0.05). Both δCu and δZn values showed significant mortality hazard ratios (HRs) in HM. The group of patients with decreased δCu and increased δZn values showed significantly poorer survival from the early phase (HR 3.9; P = 0.001), forming a unique cohort not identified based on laboratory test values. Well-known prognostic factors for HM, such as the creatinine level, and anemia-related values were highly correlated with the δZn value (P < 0.05). Time-dependent ROC curves based on the δCu or δZn value were similar to that based on the creatinine concentration (a well-known prognostic factor in HM), indicating that δCu or δZn values are useful for prognosis of HM. Variations in stable isotope ratios of essential mineral elements have thus been shown to reflect alterations in their homeostasis due to physiological changes in malignancies with higher sensitivity than concentrations do.
我们研究了血液恶性肿瘤(HM)患者血浆中 Fe、Cu 和 Zn 的同位素组成(使用多接收电感耦合等离子体质谱法)和相应浓度(使用电感耦合等离子体原子发射光谱法)的潜在变化,并评估了它们的预后能力。同时,我们还结合临床实验室检测值,从 5 年生存率预测的角度对数据进行了分析。与匹配的对照组相比,HM 患者的血浆 Cu 和 Zn 同位素比值及其浓度存在显著差异(P<0.05)。δCu 和 δZn 值均显示出 HM 患者显著的死亡危险比(HR)。与 δCu 降低和 δZn 升高的患者组相比,从早期开始的生存显著较差(HR 3.9;P=0.001),形成了一个基于实验室检测值无法识别的独特队列。HM 的已知预后因素,如肌酐水平和与贫血相关的值与 δZn 值高度相关(P<0.05)。基于 δCu 或 δZn 值的时间依赖性 ROC 曲线与基于肌酐浓度的曲线相似(肌酐是 HM 中的一个已知预后因素),表明 δCu 或 δZn 值可用于 HM 的预后。因此,必需矿物质元素的稳定同位素比值的变化表明,由于恶性肿瘤的生理变化,其体内平衡发生了改变,其敏感性高于浓度变化。